4d Pharma Share Discussion Threads

[nigelpm] 24/8/2022 14:02

Don't understand the obesession with half a million quids worth of administration fees. The same people who were shouting from the rooftops that 4d was worth billions no doubt.

[neilyb675] 24/8/2022 13:59

You have to just hope that they act with integrity. Its not as if any of this is now controllable. Don't fret about uncontrollable events.

[katsy] 24/8/2022 13:53

And have they any bargaining power, other than stringing it out as long as possible at £650/ man hour.

[neilyb675] 24/8/2022 13:48

4d aren't involved its the administrators that will be striking any deal.

[katsy] 24/8/2022 13:47

You'll be lucky if they offer more than £10m. 4d have absolutely zero bargaining power.

[blueblood] 24/8/2022 13:42

Can't Merck or SERES just offer $100m and we can all move on.....

[mr roper] 24/8/2022 13:42

Thiopia, they can publish the bid timeline. That doesn't require an nda as it is shared information for all parties. Not a big fan of this behind close door stuff. Usually ends in a carve up

[thiopia] 24/8/2022 13:32

"Offer DEADLINES have been set with all interested parties and the details of INDICATIVE OFFERS received cannot be disclosed subject to confidentiality agreement provisions."

although 4D and the Administrators have their hands tied by these NDAs I wonder what would happen if one of the bidders broke cover with a public offer to Shareholders ?

[thiopia] 24/8/2022 13:31

Mr Roper,

They have mentioned previously Non Disclosure Agreements are in place with regards to the Offers/Bids they have received. So they can't publish bid or refinancing timetables as it may breach those NDAs.

In the absence of being able to publicise the auction which is going on behind closed doors this seems to be a way of stirring the pot without stirring the pot if you know what I mean.

[sf5] 24/8/2022 09:43

Yep - can't see the point in this update other than perhaps to fester interest in prospective bidders for the IP (if any). It's all years away from any commercialisation and surely needs big pharma or similar very deep pockets and patience to take it forward.

[mr roper] 24/8/2022 09:03

Good update. More relevant to be publishing either a bid or refinancing timetable though.

[the donald] 24/8/2022 07:38

Errrr, but have they? Why release this if the company is to be sold. Has a refinance package been negotiated?

[david gruen] 24/8/2022 07:13

RNS Number : 9931W

4d Pharma PLC

24 August 2022

4D pharma plc (in administration)

4D pharma Announces Publication of Preclinical Research Showing Live Biotherapeutic MRx0006 Efficacy in Animal Model of Autism Spectrum Disorder

Leeds, UK, August 24, 2022 - 4D pharma plc (AIM: DDDD) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces the publication of pre-clinical research relating to its LBP MRx0006 for the treatment of autism spectrum disorder (ASD).

The research, published in Brain, Behaviour and Immunity, demonstrates the ability of single strain LBP MRx0006 to attenuate core behavioural deficits in a mouse model of autism, improving social deficits, repetitive and anxiety-like behaviours. Mechanistically, MRx0006 increased in the brains of ASD mice the expression of neuropeptide hormones known to regulate social and anxiety behaviour. MRx0006 also modulated the fecal microbiome metabolite profile in treated mice, which may underly the observed increases in expression of neuropeptides and their receptors, and the consequent improvements in behavioural outcomes.

"The publication of this research illustrates the continued productivity of 4D pharma's MicroRx platform, and further establishes 4D pharma as a pioneer in expanding the application of live biotherapeutics to conditions of the gut-brain axis," commented Dr. Imke Mulder, Research Director, 4D pharma. "People with autism spectrum disorder and their families are in need of new treatment approaches, and the microbiome-gut-brain axis is increasingly recognized as a key target. Importantly, with this research we are moving the field beyond associations to demonstrate the meaningful impacts that can be achieved by a single strain of bacteria, and identifying mechanisms through which the gut microbiome influences the central nervous system and behaviour."

"To our knowledge MRx0006 is the first live biotherapeutic to demonstrate the ability to target all three core behavioural deficits central to ASD, representing a novel therapeutic strategy," commented Dr Alex Stevenson, Chief Scientific Officer, 4D pharma. "Adding to our previous work in conditions of the central nervous system such as Parkinson's disease, these results further confirm the potential of human microbiota-derived therapeutics in supporting mental health by modulating the microbiota-gut-brain axis."

Sen et al., 'The live biotherapeutic Blautia stercoris MRx0006 attenuates social deficits, repetitive behaviour, and anxiety-like behaviour in a mouse model relevant to autism' Brain, Behaviour and Immunity, 2022, in press hxxps://doi.org/10.1016/j.bbi.2022.08.007

About 4D pharma

4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D pharma has developed a proprietary platform, MicroRx(R), that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has five clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA(R) (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, and Blautix(R) in irritable bowel syndrome (IBS) which has completed a successful Phase II trial. A Phase I study of MRx0005 and MRx0029 in patients with Parkinson's disease is expected to commence in 2022. Additional preclinical-stage programs include candidates for CNS disease, immune-inflammatory conditions and cancer. The Company has a research collaboration with MSD (Merck & Co., Inc., Kenilworth, NJ, USA), to discover and develop Live Biotherapeutics for vaccines.

[thiopia] 21/8/2022 21:54

"To provide a runway for a sales process, which we have assumed to be 3 months"

[bluebear1] 21/8/2022 18:32

Lol...Is that the best you got son. No wonder your mum kicked you out with tantrums like that.No worries, you can use your last few pennies to buy cheap cider to drown your sorrows.Good luck son, you will need it.Here endeth the harsh lesson.

[amaretto1] 21/8/2022 14:29

Seres mkt cap on Friday near 700 million !! Let's all just think about this for 1 minute ........

[thiopia] 21/8/2022 14:05

Due to the commercial sensitivity of this sales process, we can only provide limited narrative as to the exact PROGRESS to date.

Offer DEADLINES have been set with all interested parties and the details of INDICATIVE OFFERS received cannot be disclosed subject to confidentiality agreement provisions.

ALONGSIDE the above sale of business activity, we continue to explore the possibility of a REFINANCE of the Group and an EXIT from administration.

Similarly to above, progress here is confidential and updates will be made available to creditors at the appropriate time.

[the donald] 20/8/2022 17:14

A few more weeks only imo

[one_frankel] 20/8/2022 16:53

Fair dues buddy but we are yet to see how long it takes to unfold!

[the donald] 20/8/2022 16:38

Well I know quite a few and can talk from experience.